Literature DB >> 29292370

Polycystic kidney disease: Tolvaptan slows disease progression in late-stage ADPKD.

Albert C M Ong1.   

Abstract

Entities:  

Year:  2018        PMID： 29292370     DOI： 10.1038/nrneph.2017.180

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


× No keyword cloud information.
  10 in total

1.  Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial.

Authors:  Vicente E Torres; Eiji Higashihara; Olivier Devuyst; Arlene B Chapman; Ronald T Gansevoort; Jared J Grantham; Ronald D Perrone; John Ouyang; Jaime D Blais; Frank S Czerwiec
Journal:  Clin J Am Soc Nephrol       Date:  2016-02-23       Impact factor: 8.237

Review 2.  Autosomal dominant polycystic kidney disease: the changing face of clinical management.

Authors:  Albert C M Ong; Olivier Devuyst; Bertrand Knebelmann; Gerd Walz
Journal:  Lancet       Date:  2015-05-16       Impact factor: 79.321

3.  Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 Trial.

Authors:  Olivier Devuyst; Arlene B Chapman; Ron T Gansevoort; Eiji Higashihara; Ronald D Perrone; Vicente E Torres; Jaime D Blais; Wen Zhou; John Ouyang; Frank S Czerwiec
Journal:  J Am Soc Nephrol       Date:  2016-12-05       Impact factor: 10.121

Review 4.  The importance of total kidney volume in evaluating progression of polycystic kidney disease.

Authors:  Jared J Grantham; Vicente E Torres
Journal:  Nat Rev Nephrol       Date:  2016-10-03       Impact factor: 28.314

5.  Tolvaptan in patients with autosomal dominant polycystic kidney disease.

Authors:  Vicente E Torres; Arlene B Chapman; Olivier Devuyst; Ron T Gansevoort; Jared J Grantham; Eiji Higashihara; Ronald D Perrone; Holly B Krasa; John Ouyang; Frank S Czerwiec
Journal:  N Engl J Med       Date:  2012-11-03       Impact factor: 91.245

6.  Analysis of data from the ERA-EDTA Registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney disease.

Authors:  Edwin M Spithoven; Anneke Kramer; Esther Meijer; Bjarne Orskov; Christoph Wanner; Fergus Caskey; Frederic Collart; Patrik Finne; Damian G Fogarty; Jaap W Groothoff; Andries Hoitsma; Marie-Béatrice Nogier; Maurizio Postorino; Pietro Ravani; Oscar Zurriaga; Kitty J Jager; Ron T Gansevoort
Journal:  Kidney Int       Date:  2014-05-14       Impact factor: 10.612

7.  Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease.

Authors:  Vicente E Torres; Arlene B Chapman; Olivier Devuyst; Ron T Gansevoort; Ronald D Perrone; Gary Koch; John Ouyang; Robert D McQuade; Jaime D Blais; Frank S Czerwiec; Olga Sergeyeva
Journal:  N Engl J Med       Date:  2017-11-04       Impact factor: 91.245

Review 8.  Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice.

Authors:  Ron T Gansevoort; Mustafa Arici; Thomas Benzing; Henrik Birn; Giovambattista Capasso; Adrian Covic; Olivier Devuyst; Christiane Drechsler; Kai-Uwe Eckardt; Francesco Emma; Bertrand Knebelmann; Yannick Le Meur; Ziad A Massy; Albert C M Ong; Alberto Ortiz; Franz Schaefer; Roser Torra; Raymond Vanholder; Andrzej Więcek; Carmine Zoccali; Wim Van Biesen
Journal:  Nephrol Dial Transplant       Date:  2016-01-29       Impact factor: 5.992

Review 9.  Autosomal dominant polycystic kidney disease: recent advances in clinical management.

Authors:  Zhiguo Mao; Jiehan Chong; Albert C M Ong
Journal:  F1000Res       Date:  2016-08-18

10.  Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial.

Authors:  Vicente E Torres; Arlene B Chapman; Olivier Devuyst; Ron T Gansevoort; Ronald D Perrone; Ann Dandurand; John Ouyang; Frank S Czerwiec; Jaime D Blais
Journal:  Nephrol Dial Transplant       Date:  2018-03-01       Impact factor: 5.992
  10 in total
  5 in total

1.  Can ketogenic dietary interventions slow disease progression in ADPKD: what we know and what we don't.

Authors:  Albert C M Ong; Roser Torra
Journal:  Clin Kidney J       Date:  2022-04-21

2.  Four-jointed knock-out delays renal failure in an ADPKD model with kidney injury.

Authors:  Chiara Formica; Hester Happé; Kimberley Am Veraar; Andrea Vortkamp; Marion Scharpfenecker; Helen McNeill; Dorien Jm Peters
Journal:  J Pathol       Date:  2019-06-17       Impact factor: 7.996

3.  Long-acting somatostatin analogue treatments in autosomal dominant polycystic kidney disease and polycystic liver disease: a systematic review and meta-analysis.

Authors:  Joshua Griffiths; Mark T Mills; Albert Cm Ong
Journal:  BMJ Open       Date:  2020-01-09       Impact factor: 2.692

4.  An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International.

Authors:  Roman-Ulrich Müller; A Lianne Messchendorp; Henrik Birn; Giovambattista Capasso; Emilie Cornec-Le Gall; Olivier Devuyst; Albertien van Eerde; Patrick Guirchoun; Tess Harris; Ewout J Hoorn; Nine V A M Knoers; Uwe Korst; Djalila Mekahli; Yannick Le Meur; Tom Nijenhuis; Albert C M Ong; John A Sayer; Franz Schaefer; Aude Servais; Vladimir Tesar; Roser Torra; Stephen B Walsh; Ron T Gansevoort
Journal:  Nephrol Dial Transplant       Date:  2022-04-25       Impact factor: 7.186

Review 5.  Advances in Autosomal Dominant Polycystic Kidney Disease: A Clinical Review.

Authors:  Niloofar Nobakht; Ramy M Hanna; Maha Al-Baghdadi; Khalid Mohammed Ameen; Farid Arman; Ehsan Nobahkt; Mohammad Kamgar; Anjay Rastogi
Journal:  Kidney Med       Date:  2020-02-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.